My Cart

CD39

CD39 Overview

English NameEctonucleoside triphosphate diphosphohydrolase 1Approved Drugs0
Drugs in Clinical Trials11Target SynonymCD39 Antigen,CD39,EC 3.6.1.5,NTPDase-1,NTPDase 1,ATPDase,SPG64,EC:3.6.1.5,Ecto-ATPase 1,Lymphoid cell activation antigen,ENTPD1,Ectonucleoside Triphosphate Diphosphohydrolase 1,Ecto-ATPDase 1,Ecto-Apyrase,Ecto-ATP diphosphohydrolase 1,EC 3.6.1
Highest Development StagePhase 2 Clinical
English NameEctonucleoside triphosphate diphosphohydrolase 1
Target SynonymCD39 Antigen,CD39,EC 3.6.1.5,NTPDase-1,NTPDase 1,ATPDase,SPG64,EC:3.6.1.5,Ecto-ATPase 1,Lymphoid cell activation antigen,ENTPD1,Ectonucleoside Triphosphate Diphosphohydrolase 1,Ecto-ATPDase 1,Ecto-Apyrase,Ecto-ATP diphosphohydrolase 1,EC 3.6.1
Approved Drugs0
Drugs in Clinical Trials11
Highest Development StagePhase 2 Clinical

CD39 Background

CD39 is also known as Ectonucleoside triphosphate diphosphohydrolase 1, ENTPD1, NTPDase 1, Ecto-ATPDase 1, in the nervous system, could hydrolyze ATP and other nucleotides to regulate purinergic neurotransmission. Could also be implicated in the prevention of platelet aggregation by hydrolyzing platelet-activating ADP to AMP. Hydrolyzes ATP and ADP equally well. NTPDase-1 was originally described as CD39, a B lymphocyte cell surface marker, but it is also present on the surface of natural killer cells, T cells, and some endothelial cells.Regulatory T cells(Tregs) mediate immunosuppression through multiple, non-redundant, cell-contact dependent and independent mechanisms, a growing body of evidence suggests an important role for the CD39-CD73-adenosine pathway. CD39 ectonucleotidase is the rate-limiting enzyme of a cascade leading to the generation of suppressive adenosine that alters CD4 and CD8 T cell and natural killer cell antitumor activities.

CD39 Synonyms

CD39,ENTPD1,NTPDase 1,Entpd1,Ecto-ATPDase 1,Ecto-ATPase 1

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
TTX-030TTX-030Phase 2 ClinicalAdimab LLCLymphoma; Pancreatic Neoplasms; Solid tumours
Details
IPH-5201IPH-5201Phase 2 ClinicalInserm, Orega BiotechCarcinoma, Non-Small-Cell Lung; Lung Neoplasms; Solid tumours
Details
JS-019JS-019Phase 2 ClinicalBeijing Enrini Biotechnology Co LtdEosinophilia; Lymphoma; Solid tumours
Details
ES-014ES-014Phase 2 ClinicalElpiscience (Shanghai) Biopharma LtdNeoplasms; Solid tumours
Details
PerenostobartSRF-617Phase 1 ClinicalSurface Oncology IncProstatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours
Details
HB-0046HB0046; HB-0046Phase 1 ClinicalHuaBo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co LtdSolid tumours
Details
PUR-001PUR-001Phase 1 ClinicalPurinomia Biotech IncSolid tumours
Details
AB-598AB598Phase 1 ClinicalArcus Biosciences IncCarcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Neoplasms; Neoplasms; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms
Details
AGX-148AGX-148; AGX148Phase 1 ClinicalAgonOx IncColorectal Neoplasms; Genital Neoplasms, Female; Lung Neoplasms; Melanoma; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Urogenital Neoplasms
Details
EurestobartES-002023Phase 1 ClinicalElpiscience (Shanghai) Biopharma LtdSolid tumours
Details
ES-002ES-002Phase 1 ClinicalElpiscience (Shanghai) Biopharma LtdNeoplasms; Solid tumours
Details
  • Overview
  • Product List
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland